# Exploring Sintilimab + Bevacizumab + Decitabine for Advanced pMMR/MSS Colorectal Cancer (After 2+ Prior Therapies）

> **NCT07007767** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Union Hospital, Tongji Medical College, Huazhong University of Science and Technology** · enrollment: 32 (estimated)

## Conditions studied

- Colorectal Cancer Metastatic

## Interventions

- **DRUG:** sintilimab
- **DRUG:** Bevacizumab Biosimilar
- **DRUG:** Decitabine

## Key facts

- **NCT ID:** NCT07007767
- **Lead sponsor:** Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-06-15
- **Primary completion:** 2026-12-30
- **Final completion:** 2027-12-30
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2025-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07007767

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07007767, "Exploring Sintilimab + Bevacizumab + Decitabine for Advanced pMMR/MSS Colorectal Cancer (After 2+ Prior Therapies）". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07007767. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*